Positive acute-phase inflammatory markers in different stages of chronic kidney disease

American Journal of Nephrology

Volumn 26, Issue 1, 2006, Pages 59-66

  Romão Jr , João Egidio ^a   Haiashi, Adlei Rogério ^a   Elias, Rosilene Mota ^a   Luders, Cláudio ^a   Ferraboli, Rosiani ^a   Martins Castro, Manoel Carlos ^a   Abensur, Hugo ^a  

^a HOSPITAL BENEFICÊNCIA PORTUGUESA DE SÃO PAULO   (Brazil)

Author keywords

1 Acid glycoprotein; C reactive protein; Cardiovascular diseases; Chronic kidney disease

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; OROSOMUCOID;

ADULT; ARTICLE; CHRONIC KIDNEY DISEASE; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE MARKER; DISEASE SEVERITY; FEMALE; GLOMERULUS FILTRATION RATE; HEMODIALYSIS; HUMAN; INFLAMMATION; KIDNEY FAILURE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUALITATIVE ANALYSIS; SENSITIVITY ANALYSIS; STATISTICAL SIGNIFICANCE;

BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CHRONIC DISEASE; DIABETIC NEPHROPATHIES; FEMALE; HUMANS; KIDNEY DISEASES; MALE; MIDDLE AGED; OROSOMUCOID; RENAL DIALYSIS; SEVERITY OF ILLNESS INDEX;

EID: 33645697426     PISSN: 02508095     EISSN: None     Source Type: Journal    
DOI: 10.1159/000091806     Document Type: Article

References (37)

1. US Renal Data System: USRDS 1998 Annual Data Report. Bethesda, National Institutes of Health, National Institute of Diabetes, Digestive, and Kidney Diseases, 1998.
2. Foley RN, Parfrey PS, Sarnak MJ: Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998;32(suppl 3):112-119.
3. Luke RG: Chronic renal failure: a vasculopathic state. N Engl J Med 1998;339:841-843.
4. Levey AS, Beto JA, Coronado BE, Eknoyan G, Foley RN, Kasiske BL, Klag MJ, Mailloux LU, Manske CL, Meyer KB, Parfrey PS, Pfeffer MA, Wenger NK, Wilson PW, Wright JT: Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? What do we need to learn? Where do we go from here? Am J Kidney Dis 1998;32:853-905.
5. Morrow DA, Ridker PM: C-reactive protein, inflammation and coronary risk. Med Clin North Am 2000;84:149-161.
6. Ridker PM, Cushman M, Stampfer MJ, et al: Inflammation, aspirin, and risks of cardiovascular disease in apparently healthy men. N Engl J Med 1997;336:973-979.
7. Danesh J, Whincup P, Walker M, et al: Lowgrade inflammation and coronary heart disease: prospective study and updated metaanalysis. BMJ 2000;321:199-204.
8. Zimmermann J, Herrlinger S, Pruy A, et al: Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 1999;55:648-658.
9. Pecoits-Filho R, Bárány P, Lindholm B, et al: Interleukin-6 is an independent predictor of mortality in patients starting dialysis treatment. Nephrol Dial Transplant 2002;17:1684-1688.
10. Stenvinkel P, Alvestrand A: Inflammation in end-stage renal disease: sources, consequences, and therapy. Semin Nephrol 2002;15:329-337.
11. Lagrand WK, Visser CA, Hermens WT, et al: C-reactive protein as a cardiovascular risk factor. More than an epiphenomenon? Circulation 2000;100:96-102.
12. Torzewski M, Rist C, Mortensen RF, et al: C-reactive protein in the arterial intima: role of C-reactive protein receptor dependent monocytes recruitment in atherogenesis. Arterioscler Thromb Vasc Biol 2000;20:2094-2099.
13. Kazmierczak M, Sobieska M, Wiktorowicz K, Wysocki H: Changes of acute phase proteins glycosylation profile as a possible prognostic marker in myocardial infarction. Int J Cardiol 1995;49:201-207.
14. Mariotti R, Musumeci G, De Carlo M, et al: Acute-phase reactants in acute myocardial infarction: impact on 5-year prognosis. Ital Heart J 2001;2:294-300.
15. Casl MT, Surina B, Glojnaric-Spasic I, et al: Serum amyloid A protein in patients with acute myocardial infarction. Ann Clin Biochem 1995;32:196-200.
16. Pereira BJ, Shapiro L, King AJ, et al: Plasma levels of IL-1 beta, TNF alpha and their specific inhibitors in undialyzed chronic renal failure, CAPD and hemodialysis patients. Kidney Int 1994;45:890-896.
17. Nakanishi I: Interleukin-8 in chronic renal failure and dialysis patients. Nephrol Dial Transplant 1994;9:1435-1442.
18. Pecoits-Filho R, Heimbürger O, Bárány P, et al: Association between inflammatory markers and residual renal function in CRF patients. Am J Kidney Dis 2003;41:1212-1218.
19. Panichi V, Migliori M, De Pietro S, et al: C-reactive protein in patients with chronic renal diseases. Ren Fail 2001;23:551-562.
20. Levey AS, Bosch JP, Lewis JB, et al: A more accurate method to estimate glomerular function rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130:461-470.
21. National Kidney Foundation: K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002;39(suppl 1): S1-S246.
22. Don BR, Rosales LM, Levine NW, et al: Leptin is a negative acute phase protein in chronic hemodialysis patients. Kidney Int 2001;59: 1114-1120.
23. Stuveling EM, Hillege HL, Bakker SJL, et al: C-reactive protein is associated with renal function abnormalities in a non-diabetic population. Kidney Int 2003;63:654-661.
24. Wang AY, Wang M, Woo J, et al: A novel association between residual renal function and left ventricular hypertrophy in peritoneal dialysis patients. Kidney Int 2002;62:639-647.
25. Kaysen GA: The microinflammatory state in uremia: causes and potential consequences. J Am Soc Nephrol 2001;12:1549-1557.
26. Chung SH, Heimbürger O, Stenvinkel P, Bergström J, Lindholm B: Association between inflammation and changes in residual renal function and peritoneal transport rate during the first year of dialysis. Nephrol Dial Transplant 2001;16:2240-2245.
27. Niebauer J, Volk HD, Kemp M, et al: Endotoxin and immune activation in chronic heart failure: a prospective cohort study. Lancet 1999;353:1838-1842.
28. Miyata T, Ueda Y, Shinzato T, et al: Accumulation of albumin-linked and free-form pentosidine in the circulation of uremic patients with end-stage renal failure. J Am Soc Nephrol 1996;7:1198-1206.
29. Himmelfard J, Stenvinkel P, Ikzler TA, Hakim RM: The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 2002;62:1524-1538.
30. van Riemsdijk-van Overbeeke IC, Baan C, Hesse CJ, et al: TNF-alpha: mRNA, plasma protein levels and soluble receptors in patients on chronic hemodialysis, on CAPD and with end-stage renal failure. Clin Nephrol 2000;53:115-123.
31. Torre-Amione G, Kapadia S, Benedict C, et al: Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol 1996;27:1201-1206.
32. Agalou S, Ahmed N, Thornalley PJ, Dawnay A: Advanced glycation end product free adducts are cleared by dialysis. Ann NY Acad Sci 2005;1043:734-739.
33. Stenvinkel P: Inflammation in end-stage renal failure: could it be treated? Nephrol Dial Transplant 2002;17(suppl 8):33-38.
34. Bemelmans MH, Gouma DJ, Buurman WA: Influence of nephrectomy on tumor necrosis factor clearance in a murine model. J Immunol 1993;150:2007-2017.
35. Espinoza M, Aguilera A, Auxiliadora Bajo M, et al: Tumor necrosis factor alpha as a uremic toxin: correlation with neuropathy, left ventricular hypertrophy, anemia, and hypertriglyceridemia in peritoneal dialysis patients. Adv Perit Dial 1999;15:82-86.
36. Wang T, Ye RG, Zhen ZH, et al: Influence of peritoneal dialysis on the progression of chronic renal failure. Adv Perit Dial 1995;11:139-141.
37. Vanholder R, Argiles A, Baurmeister U, et al: Uremic toxicity: present state of art. Int J Artif Organs 2001;24:695-725.